Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy

The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxiciti...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiao, Wang, Yao, Wei, Jianshu, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884912/
https://www.ncbi.nlm.nih.gov/pubmed/31783889
http://dx.doi.org/10.1186/s13045-019-0813-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884912/
https://www.ncbi.nlm.nih.gov/pubmed/31783889
http://dx.doi.org/10.1186/s13045-019-0813-7

Ejemplares similares